Calliditas Therapeutics AB (publ)
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CALT research report →
Range $39 – $40
Price Chart
About the company
Calliditas Therapeutics AB is a clinical-stage biopharmaceutical company, established in Stockholm, Sweden in 2004. Its core business is to discover, develop, and commercialize pharmaceutical treatments for rare diseases, initially concentrating on conditions affecting the kidneys and liver. The company's portfolio features Nefecon, an oral budesonide immunosuppressant designed to treat immunoglobulin A nephropathy, an autoimmune renal disease.
- CEO
- Renee Aguiar-Lucander
- IPO
- 2020
- Employees
- 222
- HQ
- Stockholm, SE
Get TickerSpark's AI analysis on CALT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.15B
- P/E
- -23.94
- Fwd P/E
- 0.56
- PEG
- 0.41
- P/S
- 9.31
- P/B
- 33.34
- EV/EBITDA
- -30.57
- Div Yield
- 0.00%
- Gross Margin
- 93.62%
- Op Margin
- -31.85%
- Net Margin
- -38.63%
- ROE
- -84.68%
- ROIC
- -25.53%
Latest fiscal year · YoY change
- Revenue
- $1.21B+50.3%
- Gross Profit
- $1.13B+43.4%
- Op Income
- $-384,397,000
- Net Income
- $-466,185,000-13.1%
- EPS
- $-17.38-11.7%
- OCF Growth
- -39.6%
- FCF Growth
- -42.6%
- 52W High
- $43.00
- 52W Low
- $15.25
- 50D MA
- $39.65
- 200D MA
- $29.60
- Beta
- 1.46
- RSI (14)
- 51
- Avg Volume
- 7.73K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Calliditas delivered a record Q2 on TARPEYO/Nefecon demand, beat its operating profitability target, and raised full-year franchise revenue guidance while also highlighting positive pipeline data and an ongoing Asahi Kasei takeover offer.· August 13, 2024
- Q2 net revenues were SEK 559.8 million versus SEK 269.4 million a year ago, driven by TARPEYO net product sales of SEK 493.4 million ($46.3 million), up 90% year over year.
- The company said it achieved adjusted operating profit of SEK 70.2 million, before SEK 101.7 million of deal- and share-price-related costs; reported operating loss was SEK 31.5 million.
- TARPEYO demand remained strong with 750 new enrollments in Q2, 343 new prescribers, and more than 2,300 healthcare providers prescribing the drug.
- Management raised 2024 revenue guidance for the Nefecon franchise to $165 million-$185 million, citing continued demand and improved payer coverage after full approval.
- Pipeline updates were positive: setanaxib met its primary endpoint in PBC, and Kinpeygo received full approval in Europe, triggering a EUR 10 million milestone payable in Q3.
Q2 2024 net revenues were SEK 559.8 million, up from SEK 269.4 million in Q2 2023. TARPEYO net product sales were SEK 493.4 million ($46.3 million), up 90% year over year, while partnership revenues were SEK 66.4 million versus SEK 10.1 million a year ago. Gross margin was not stated. Operating expenses were SEK 537.8 million versus SEK 330.3 million, and operating loss was SEK 31.5 million versus SEK 75.2 million last year; adjusted operating profit excluding Asahi Kasei offer costs and incentive-related provisions was SEK 70.2 million. Cash flow used in operating activities was SEK 7 million, and cash at quarter-end was SEK 797.3 million. For 2024, management raised revenue guidance for the Nefecon franchise to USD 165 million to USD 185 million.
Renée Aguiar-Lucander emphasized that Q2 was both commercially and strategically strong, calling it a record revenue quarter and noting the company hit its operating profitability target earlier than planned. She pointed to full approval, reduced payer friction, strong TARPEYO demand, new scientific data, and the China launch as evidence that the Nefecon franchise is gaining momentum. Her tone was upbeat but measured, while also acknowledging the ongoing Asahi Kasei offer and its associated costs.
Fredrik Johansson detailed the quarter’s financials, including SEK 559.8 million in revenue, SEK 537.8 million in operating expenses, and a SEK 31.5 million operating loss. He broke out SEK 101.7 million of costs tied to the Asahi Kasei offer and social security provisions for incentive programs, and said that excluding those items the company posted an adjusted operating profit of SEK 70.2 million. He also highlighted cash used in operating activities of SEK 7 million, a net cash decrease of SEK 11.2 million, and a healthy cash balance of SEK 797.3 million.
There was no Q&A session, so no analyst questions were taken. The most notable management commentary centered on full approval of TARPEYO and improved payer alignment, with more than 80% of U.S. commercially covered lives now under policies aligned with the new label or reduced UPCR thresholds. Management also highlighted positive pipeline readouts for setanaxib in PBC and the full European approval for Kinpeygo, which triggered a EUR 10 million milestone in Q3.
The bull case from this call is that TARPEYO/Nefecon is still accelerating, with record enrollments, new prescribers, and better payer access translating into strong revenue growth. Management also said the franchise is already operating profitably on an adjusted basis and raised full-year guidance, while the pipeline added encouraging setanaxib and PBC data.
The main risks are the large amount of non-operating costs tied to the Asahi Kasei offer and incentive provisions, which pushed reported operating results back into a loss despite strong underlying performance. Management also noted ongoing dependence on payer policy changes and continued education efforts, and there was no Q&A to probe sustainability, competitive pressure, or the timing of future milestones.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 2.5%
- Shares Outstanding
- 26.84M
- Float Shares
- 338.38K
of shares held by institutions
21 13F filers
Our CALT coverage
Recent articles, reports, and earnings notes.
No research on CALT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CALT report →Financial Survey: MindWalk (NASDAQ:HYFT) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
defenseworld.net · Mar 10
Analyzing Cyclacel Pharmaceuticals (NASDAQ:BGMS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
defenseworld.net · Feb 7
Calliditas Therapeutics AB (publ) (NASDAQ:CALT) & Palatin Technologies (PINK:PTNT) Critical Analysis
defenseworld.net · Jan 26
Head-To-Head Review: AngioSoma (OTCMKTS:SOAN) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT)
defenseworld.net · Jan 2
Evofem Biosciences (NASDAQ:EVFM) & Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Head-To-Head Survey
defenseworld.net · Nov 2
Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm
prnewswire.com · Sep 16
Notice of extraordinary meeting of Calliditas Therapeutics AB (publ)
prnewswire.com · Sep 3
Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei
prnewswire.com · Sep 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.